America’s fisheries are among the world’s richest in abundance and diversity. They provide scientific, aesthetic, recreational, commercial, subsistence, cultural, social, and economic benefits. FAC leads aquatic resource management for the Service and strives to invest its resources in the nation’s highest priority aquatic conservation and water-based recreational needs. Fish health is a critical component of healthy fisheries and core to the work of the Fish and Aquatic Conservation Program.
The Aquatic Animal Drug Approval Partnership (AADAP) program is part of the Fish and Aquatic Conservation fish health work. It is the only program in the United States singularly dedicated to obtaining U.S. Food and Drug Administration (FDA) approval of new medications needed for use in fish culture and fisheries management. Since the late 1990’s, AADAP has contributed to virtually every new fish medication approved by the FDA. Ultimately, the AADAP program allows fisheries professionals to more effectively and efficiently rear and manage a variety of fish species to meet production goals, stock healthy fish, and maintain a healthy environment.
Information to inform decisions regarding which medication to use, and how to use it. Safe, effective medications for treating fish diseases and managing fisheries—as well as informing the professionals who administer these medications—are growing needs.More
Investigational New Animal Drugs (INADs) are available through the National INAD Program (NIP) and can be used as long as study parameters are met and work is being done to reach full drug approval.More
Researchers use sound science to evaluate the safety and effectiveness of experimental fish medications. Results support FDA approval of the medications.More
The AADAP Program would like to present two new products this month. Please take a few minutes to view the INAD infographic as well as a 60 second video highlighting the AADAP Program.
INAD Infographic: The Investigational New Animal Drug (INAD) infographic is straightforward, eye-catching, and sharable.
Fish Bytes: Developed in collaboration with the U.S. Fish and Wildlife Service, National Conservation Training Center’s Division of Training Support and Heritage. This 60-second video showcases the overall goal of the Aquatic Animal Drug Approval Partnership Program.
CVM approved the supplemental new animal drug application (NADA) for Terramycin® 200 for Fish. The supplemental approval of Terramycin® 200 for Fish (oxytetracycline) Type A medicated article provides for a change in the bacterial species of Aeromonas liquefaciens to Aeromonas hydrophila in the approved indications for salmonids and catfish.
Don't miss out on the next issue of the AADAP Update. The Update is a monthly publication providing recent news and updates from the Aquatic Animal Drug Approval Partnership program and its partners. Please email to subscribe.